Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

GU Cancers 2019 | Sacituzumab govitecan in the treatment of metastatic urothelial carcinoma

Jeanny Aragon-Ching, MD, FACP, of the Inova Schar Cancer Institute, Fairfax, Canada, speaks at the 2019 Genitourinary Cancers Symposium, held in San Francisco, CA, where she discusses the promising response rates in the use of the antibody-drug conjugate sacituzumab govitecan in the treatment of metastatic urothelial carcinoma from the TROPHY U-01 study (NCT03547973).